Rani Therapeutics Holdings (RANI) Price & Analysis

Compare

1,181 Followers

RANI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.39 - $3.75

Previous CloseN/A

Volume228.85K

Average Volume (3M)506.45K

Market Cap

$35.68M

Enterprise Value$26.10M

Total Cash (Recent Filing)$10.22M

Total Debt (Recent Filing)$19.39M

Price to Earnings (P/E)―

Beta0.67

Next Earnings

Nov 12, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding47,898,228

10 Day Avg. Volume288,430

30 Day Avg. Volume506,446

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue21.75

Enterprise Value/Gross Profit37.24

Enterprise Value/Ebitda-0.54

Forecast

1Y Price Target

$9.00

Price Target Upside1736.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Innovative TechnologyRaniPill delivery demonstrated comparable bioavailability to the subQ route of delivery for both molecules studied.

Market PotentialThe obesity market is massive, with ~70M obese American adults, creating potential for multiple players and the versatility of RaniPill could enable further partnerships or internal development programs as obesity drugs come off-patent.

Strategic PartnershipRani entered into a research agreement with Chugai Pharmaceutical Co., indicating a significant collaboration.

Bears Say

Clinical RisksRisks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.

Financial PerformanceRani Therapeutics reported 1Q25 results with a net loss of ($12.7M) and ended the period with $15.9M in cash, indicating the company will require additional capital in the near term.

Funding RequirementRani disclosed a letter agreement with an existing investor resulting in gross proceeds of $4.3M from warrant exercise, highlighting the need for additional funding.

Rani Therapeutics Holdings News

Rani Therapeutics Reports Q2 2025 Financial Results

Rani Therapeutics Holdings, Inc. Class A ( ($RANI) ) has released its Q2 earnings. Here is a breakdown...

1M ago

RANI

Rani Therapeutics files $200M mixed securities shelf

16:08 EDT Rani Therapeutics (RANI) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

RANI

Rani Therapeutics Announces New Securities Purchase Agreement

Rani Therapeutics Holdings ( ($RANI) ) has issued an announcement. On July 14, 2025, Rani Therapeutics Holdings entered...

2M ago

RANI

Rani Therapeutics prices 4.35M shares at 40c in registered direct offering

Rani Therapeutics (RANI) entered into a securities purchase agreement with a single institutional investor for the purchase and...

2M ago

RANI

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO

Genelux Corporation (GNLX) announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and...

3M ago

GNLX

RANI

Rani files to sell 13.16M shares of Class A common stock for holders

14:51 EDT Rani files to sell 13.16M shares of Class A common stock for holders Published first on...

3M ago

RANI

Rani Therapeutics Faces Nasdaq Non-Compliance Notice

The latest update is out from Rani Therapeutics Holdings ( ($RANI) ). On June 20, 2025, Rani Therapeutics...

3M ago

RANI

Rani Therapeutics Approves Key Proposals at Annual Meeting

Rani Therapeutics Holdings ( ($RANI) ) has issued an announcement. On May 28, 2025, Rani Therapeutics Holdings held...

4M ago

RANI

Rani Therapeutics: Strategic Partnerships and Financial Strength Justify Buy Rating

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Rani Therapeutics Holdings (RANI – Research Report),...

4M ago

RANI

Rani Therapeutics Secures $4.3M via Series D Warrant

The latest announcement is out from Rani Therapeutics Holdings ( ($RANI) ). On May 20, 2025, Rani Therapeutics...

4M ago

RANI

Rani Therapeutics announces research agreement with Chugai

Rani Therapeutics (RANI) announced the company has entered into a Research Agreement on 13th August, 2024, for two...

4M ago

RANI

Rani Therapeutics: Strategic Advancements in Obesity Treatment Justify Buy Rating

Rani Therapeutics Holdings (RANI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

4M ago

RANI

Rani Therapeutics price target lowered to $4 from $14 at Oppenheimer

Oppenheimer lowered the firm’s price target on Rani Therapeutics (RANI) to $4 from $14 and keeps an Outperform...

4M ago

RANI

Rani Therapeutics Highlights Promising Preclinical Data

Rani Therapeutics Holdings, Inc. Class A ( ($RANI) ) has released its Q1 earnings. Here is a breakdown...

4M ago

RANI

RANI FAQ

What was Rani Therapeutics Holdings’s price range in the past 12 months?

Rani Therapeutics Holdings lowest stock price was $0.39 and its highest was $3.75 in the past 12 months.

What is Rani Therapeutics Holdings’s market cap?

Rani Therapeutics Holdings’s market cap is $35.68M.

When is Rani Therapeutics Holdings’s upcoming earnings report date?

Rani Therapeutics Holdings’s upcoming earnings report date is Nov 12, 2025 which is in 47 days.

How were Rani Therapeutics Holdings’s earnings last quarter?

Rani Therapeutics Holdings released its earnings results on Aug 07, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.285 by $0.105.

Is Rani Therapeutics Holdings overvalued?

According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rani Therapeutics Holdings pay dividends?

Rani Therapeutics Holdings does not currently pay dividends.

What is Rani Therapeutics Holdings’s EPS estimate?

Rani Therapeutics Holdings’s EPS estimate is -0.11.

How many shares outstanding does Rani Therapeutics Holdings have?

Rani Therapeutics Holdings has 47,898,228 shares outstanding.

What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?

Rani Therapeutics Holdings reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.285. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Rani Therapeutics Holdings?

Currently, no hedge funds are holding shares in RANI

Rani Therapeutics Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

-1372.59%

Trailing 12-Months

Asset Growth

-61.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rani Therapeutics Holdings

Rani Therapeutics Holdings (RANI) is a healthcare company focused on developing innovative oral biologics utilizing its proprietary RaniPill technology. The company operates within the biotechnology and pharmaceutical sectors, offering a unique solution for the oral delivery of biologics, which are traditionally administered via injection. Rani's core product, the RaniPill capsule, is designed to deliver large-molecule drugs through the gastrointestinal tract, thereby improving patient compliance and expanding the potential market for biologic therapies.